Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''

Detalles Bibliográficos
Autores principales: Shinozaki, Eiji, Yoshino, Takayuki, Tsuchihara, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943345/
https://www.ncbi.nlm.nih.gov/pubmed/29563632
http://dx.doi.org/10.1038/s41416-018-0040-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943345/
https://www.ncbi.nlm.nih.gov/pubmed/29563632
http://dx.doi.org/10.1038/s41416-018-0040-y

Ejemplares similares